ENDO HEALTH SOLUTIONS $39.30

up +0.52


17/6/2013 04:17 PM  |  NASDAQ : ENDP  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Get Trend Analysis Icon Get ENDP Trend Analysis - it has outperformed the S&P 500 by 12%

Partner Headlines

  1. Benzinga's M&A Chatter for Wednesday January 30, 2013

    Benzinga

  2. Mid-Afternoon Market Update: RIMM Falls Further, Endo Health Rises ...

    Benzinga

  3. UPDATE: Stifel Nicolaus Cuts PT to $26.50 on Endo Health Solutions ...

    Benzinga

  4. RBC Says 'Not Enough Clarity on Near-Term Issues Facing' Endo ...

    Benzinga

  5. Stocks Hitting 52-Week Lows

    Benzinga

  6. UPDATE: Piper Jaffray Downgrades Endo Health Solutions to Neutral, ...

    Benzinga

  7. UPDATE: JP Morgan Cuts PT to $35 on Endo Health Solutions Ahead of ...

    Benzinga

  8. Endo Health Solutions Offers Comment on Dismissal of Suit Against FDA

    Benzinga

  9. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga

  10. Benzinga's Top Pre-Market Losers

    Benzinga

  11. UPDATE: Endo Health Solutions Announces CEO Transition Plan; Won't ...

    Benzinga

  12. Endo Health Solutions Launches 7.5mg, 15mg Strengths of ...

    Benzinga

  13. When Follow-Through Occurs, Watch Strong Industries

    Investors Business Daily

  14. UPDATE: Stifel Nicolaus Cuts PT to $40 on Endo Health Solutions on ...

    Benzinga

  15. Endo Pharmceutical Sues FDA, Claiming Safety Concerns: Protecting ...

    YCharts

  16. Endo Health Solutions Confirms FDA Suit Related to Non-Tamper ...

    Benzinga

  17. Endo Pharmaceutical Holdings, Inc. (ENDP) CEO David Holveck buys ...

    GuruFocus

  18. Endo Health Offers Prelim. Data Showing 59% Drop in Abuse of ...

    Benzinga

  19. Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q)

    GuruFocus

  20. Watson Pharma Starts New Era As Generic Drug Titan

    Investors Business Daily

  21. FDA Warns of 'Serious Blood Disorder' from Endo Health Solutions

    FOXBusiness

  22. UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on ...

    Benzinga

  23. Benzinga's Top Downgrades

    Benzinga

  24. Endo Health Solutions Announces Receipt of Paragraph IV ...

    Benzinga

  25. Watson Pharmaceuticals In Buy Area Above 81.10 Entry

    Investors Business Daily

  26. Stocks Move Ahead, But On Track For Weekly Losses

    Investors Business Daily

  27. Watson Stock Hits High On Generic Lidoderm Approval

    Investors Business Daily

  28. Stocks Turn Higher Near Midday; Watson Pharmaceuticals Jumps

    Investors Business Daily

  29. Statement on FDA Decision Regarding Endo Citizen Petition and ...

    Benzinga

  30. Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q)

    GuruFocus

  31. Sirius XM Radio, MGM Mirage Among Stocks Up on High Volume Tuesday

    FOXBusiness

  32. A Peek Into The Market Before The Trading Starts

    Benzinga

  33. Health Care Sector Wrap

    FOXBusiness

  34. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga

  35. Weekly Top Insider Buys: MDT, KMI, WIN, ENDP, OC

    GuruFocus

  36. Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP

    GuruFocus

  37. Cantor Fitzgerald Reiterates Hold Rating, $37 PT for Endo Health ...

    Benzinga

  38. UPDATE: Stifel Nicolaus Reduces PT to $50 on Endo Pharmaceuticals ...

    Benzinga

  39. UPDATE: Cantor Fitzgerald Reduces PT to $37 on Endo ...

    Benzinga

  40. Endo, Watson Agree To Launch Generic Lidoderm

    Investors Business Daily

  41. Endo Announces Resolution of Patent Litigation with Watson ...

    Benzinga

  42. Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-K)

    at GuruFocus

  43. Endo Q4 income surges 32%

    at IBD

  44. Stock Market Ends Mixed With Lower Volume

    at IBD

  45. Stocks Turn Mixed In Afternoon Amid Conflicting Data

    at IBD

  46. Stocks Up In Early Afternoon Amid Mixed Economic Data

    at IBD

  47. Notable Call Options Activity in Endo Pharmaceuticals

    at Benzinga

  48. Endo Earnings Top Estimates, But 2012 Guidance Lags

    at IBD

  49. Financial Breakfast: Morning News Summary for February 24, 2012

    at Benzinga

  50. Earnings Scheduled For February 24

    at Benzinga

  51. Goldman Sachs Maintains Neutral, $37 Target on Endo Pharmaceuticals

    at Benzinga

  52. BioDelivery Sciences Receives Patent Allowance Triggering $15 ...

    at Benzinga

  53. Endo Diversifies Drug Lineup To Offset Generic Threat

    at IBD

  54. Biotechs, HMOs, Digital Records Push Aid Health Stocks

    at IBD

  55. Shares of BioDelivery Sciences Are Up 13% After Licensing ...

    at Benzinga

  56. Endo Pharmaceuticals Sees an Upswing in Put Activity

    By SchaeffersResearch

  57. Notable Put Options Activity in Endo Pharmaceuticals

    at Benzinga

  58. Benzinga's Microcap Movers for Friday January 6, 2012

    at Benzinga

  59. BioDelivery Sciences Popping 160% On License and Development Agreement

    at Benzinga

  60. Citigroup Maintains Buy, $48 Target on Endo Pharmaceuticals

    at Benzinga

  61. Apple, 3 Other Techs In IBD 50 Start And End Of 2011

    at IBD

  62. America's Best Companies Are Cheap - So Merry Christmas and a ...

    at GuruFocus

  63. Stocks Finish Down but off Afternoon Lows

    At Market Intelligence Center

  64. Endo Pharmaceuticals (ENDP) Gains 6% after FDA OKs Crush-Resistant ...

    At Market Intelligence Center

  65. Endo crush-proof drug OK'd

    at IBD

  66. Concerns About Deal in Europe Drives Stocks Lower

    At Market Intelligence Center

  67. Is Endo Pharmaceuticals Going to Seize Market Share?

    at Benzinga

  68. Benzinga's Volume Gainers

    at Benzinga

  69. Benzinga's Top Pre-Market Gainers

    at Benzinga
People viewing ENDP also viewed: , , , , , ,
Marketplace
Trading Center